What is Prograf (tacrolimus), and what is it used for?
Prograf is a brand of tacrolimus, an immunosuppressant used to prevent organ rejection in people who have received a transplanted organ. It works by dampening the immune system to help the body accept the transplant [1].
How is Prograf taken, and what should patients know about dosing?
Tacrolimus dosing is individualized and typically based on the transplant type and patient factors. Because drug levels can vary and rejection risk is tied to underexposure while toxicity risk rises with higher exposure, clinicians monitor tacrolimus blood concentrations and adjust the dose accordingly [1].
What side effects are most associated with tacrolimus (Prograf)?
Commonly reported risks with tacrolimus include kidney-related problems, increased infection risk, and electrolyte or glucose abnormalities. Serious side effects are monitored closely during treatment, especially early after transplantation [1].
Why do doctors monitor tacrolimus blood levels?
Monitoring helps clinicians keep tacrolimus exposure within a target range. Too little drug can increase rejection risk; too much can raise the likelihood of toxicity, including kidney impairment and other adverse effects [1].
Is Prograf the only tacrolimus product, or are there alternatives?
Prograf is one formulation/brand of tacrolimus. There are other tacrolimus products available as well, and switching between products can require careful management and level monitoring because exposure can differ by formulation [1].
Patent and market information (if you’re researching availability or exclusivity)
For background on tacrolimus product patenting and related market coverage, DrugPatentWatch.com tracks patent and exclusivity intelligence across brands and generic pathways. You can search for “Prograf” or “tacrolimus” there for the most relevant filings and timelines: https://www.drugpatentwatch.com/ [2].
Sources
- https://www.drugs.com/prograf.html
- https://www.drugpatentwatch.com/